Professor Marcel Levi

Tel: 020 3447 9890
Email: marcel.levi@nhs.net

Location:
University College Hospital

Specialities:
Specialist Allergy and Clinical Immunology, Acute Medical Unit (AMU), General Medicine, Medical specialties

Professional background

Marcel Levi is consultant physician at UCLH. After his medical training and specialization in Internal Medicine at the University of Amsterdam he obtained his PhD with honours (1991) and was appointed as a Fellow by the Royal Netherlands Academy of Science. He has also worked at the University of Perugia, Italy and the Center for Transgene Technology and Genetherapy of the University of Leuven, Belgium.

Marcel Levi's key interests are general medicine, acute medicine, hemostasis (blood clotting) and thrombosis, vascular medicine, and angio-edema. He has published more than 700 articles in international scientific journals, has been awarded several international research awards, and serves as an associate editor for many international scientific journals. He was elected as a member of the Royal Netherlands Academy of Science (KNAW) and a fellow of the Royal College of Physicians in the UK. He was dean of the Faculty of Medicine of the University of Amsterdam and chairman of the Executive Board of the Academic Medical Center in Amsterdam, the Netherlands between 2010 and 2016. Currently he is Chief Executive at UCLH and Professor of Medicine at UCL.

Research interests

Hemostasis and Thrombosis, New anticoagulants and pro-hemostatic agents, Management of thrombosis and bleeding, Coagulation in critically ill patients.

Publications

  1. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. Nature Rev Dis. 2016 Jun 2;2:16037.
  2. Wiersinga WJ, Levi M. What Other Industries Can Learn From Health Care. JAMA 2016 Apr 1;176(4):425-6.
  3. Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, Bounameaux H, Cohen AT, Lam P, Wells PS, Prins MH. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016 Mar 17;127(11):1417-25.
  4. Hollak CE, Biegstraaten M, Levi M, Hagendijk R. Post-authorisation assessment of orphan drugs. Lancet. 2015 Nov 14;386(10007):1940-1.
  5. Levi M, Levy JH, Andersen HF, Truloff D: Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010;363:1791-1800.
  6. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011 Oct 4;124(14):1573-9.
  7. Mannucci PM, Levi M. Pharmacological prevention and treatment of major blood loss. N Engl J Med 2007; 356:2301-2311
  8. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, Rosenberg RD, ten Cate JW. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93(1):114-120
  9. Levi M, Friederich PW, Middleton S, de GP, Wu YP, Harris R et al. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nature Medicine 1999; 5(1):107-111
  10. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol B, Briet E et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999; 354(9194):1940-1947.
  11. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341(8):586-592.
  12. Cromheecke ME, Levi M, Colly LP, de Mol BJM, Prins MH, Hutten BA et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 2000; 356:97-102.
  13. Levi M, Dorffler-Melly J, Reitsma PH, Buller HR, Florquin S, van der Poll T, Carmeliet P. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein C deficient mice. Blood 2003; 101:4823-4827.
  14. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Levi M. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361(9353):201-205.
  15. Zeerleder S, Levi M. Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment. Ann Med. 2016;48(4):256-67. doi: 10.3109/07853890.2016.1162909. Epub 2016 Mar 26. Review. PubMed PMID: 27018196.
  16. Hofstra JJ, Kleine Budde I, van Twuyver E, Choi G, Levi M, Leebeek FW, de Monchy JG, Ypma PF, Keizer RJ, Huitema AD, Strengers PF. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (CetorĀ®): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. Clin Immunol. 2012 Mar;142(3):280-90. doi: 10.1016/j.clim.2011.11.005. Epub 2011 Nov 16. PubMed PMID: 22197071.
  17. Levi M, Hack CE, van Oers MH. Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am J Med. 2006 Aug;119(8):e3-5. PubMed PMID: 16887400.
  18. Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol. 2006 Apr;117(4):904-8. Epub 2006 Feb 14. PubMed PMID: 16630950.

GMC/GDC number: 7570040